efficacy of diclofenac on pancreatitis

efficacy of Diclofenac suppository on treatment of acute biliary pancreatitis

Status

Active, not recruiting

Phases

Phase 3

Study type

Interventional

Source

IRCT

Registry ID

IRCT20181028041485N1

Enrollment

Registered

2019-02-12

Start date

2017-03-20

Completion date

Unknown

Last updated

2019-02-25

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Pancratitis. Biliary acute pancreatitis

Interventions

Intervention 1: Intervention group: Diclofenac Suppository 100 mg every 8 hours will be added until symptom improvement and the day before surgery. Intervention 2: Control group: Placebo Suppository e

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Inclusion criteria

Inclusion criteria: Acute pancreatitis, which in its definition should have at least two criteria of the following three criteria: a) pain in the upper abdomen, b) serum amylase or lipase> 3 times of normal, orc) acute pancreatitis features In computer tomography (CT) or magnetic resonance imaging (MRI) A biliary cause based on at least one of the following conditions: a) gallstone or sludge in the imaging (any type); b) common bile duct > 8 mm in patients 10 mm in patients> 75 years of age. C) Alanine aminotransferase (AST) more than twice as normal; Conscious informed consent; Age older than 18 years.

Exclusion criteria

Exclusion criteria: Cholangitis Pancreatitis for other causes such as alcohol abuse, metabolic causes (hyperthermia or hypercalcemia), medication, trauma, etc. Chronic pancreatitis Pregnancy

Design outcomes

Primary

Measure	Time frame
Mortality. Timepoint: End of the research. Method of measurement: Number of people.;Organ failure. Timepoint: End of the research. Method of measurement: Lab test & physical exam.;Necrotizing pancratitis. Timepoint: End of the research. Method of measurement: Abdominal & pelvic CT scan.;Bacteremia. Timepoint: During the study. Method of measurement: Lab test.;Cholangitis. Timepoint: During the study. Method of measurement: Lab test & physical exam.;Need for necrozectomy surgery. Timepoint: During the study. Method of measurement: Abdominal & pelvic CT scan.;Number of ICU & hospital admissions days. Timepoint: End of the research. Method of measurement: Number of days.	—

Measure

Time frame

Mortality. Timepoint: End of the research. Method of measurement: Number of people.;Organ failure. Timepoint: End of the research. Method of measurement: Lab test & physical exam.;Necrotizing pancratitis. Timepoint: End of the research. Method of measurement: Abdominal & pelvic CT scan.;Bacteremia. Timepoint: During the study. Method of measurement: Lab test.;Cholangitis. Timepoint: During the study. Method of measurement: Lab test & physical exam.;Need for necrozectomy surgery. Timepoint: During the study. Method of measurement: Abdominal & pelvic CT scan.;Number of ICU & hospital admissions days. Timepoint: End of the research. Method of measurement: Number of days.

—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactMorteza Yousefi

Sanandaj University of Medical Sciences

Yousefi.M@Muk.ac.ir+98 87 3361 1258

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026